Biora Therapeutics announces new patents for its NaviCap platform

Biora Therapeutics announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap targeted oral delivery platform under development. The patents are directed to methods of treating ulcerative colitis using an ingestible device that delivers one or more therapeutic agents to the proximal part of the large intestine. “The NaviCap platform has the potential to transform treatment options for many diseases of the gastrointestinal tract by enabling more effective delivery of therapeutics directly to the site of disease in the intestine,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “These patents expand our coverage for additional therapeutic targets as we continue to strengthen our intellectual property portfolio.”